SLC5A2 and diabetes mellitus: Additionally, a randomized, controlled trial in patients with diabetes found that treatment with the SGLT2 inhibitor, dapagliflozin, was associated with a significant improvement in LV diastolic dysfunction assessed with diastolic stress echocardiography compared with placebo [50].